AmpliPhi Announces Departure of CEO Jeremy Curnock Cook, Ampliphi's Chairman, Named Interim CEO Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia

AmpliPhi Announces Departure of CEO

Jeremy Curnock Cook, Ampliphi's

Chairman, Named Interim CEO

Richmond, VA, USA, Ljubljana,

Slovenia, and Sydney, Australia, September 19, 2014 - AmpliPhi BioSciences Corporation (OTC:APHB) ("AmpliPhi"),

the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today

announced that Philip J. Young has stepped down from his role as President and CEO. Mr Young's resignation was by mutual

agreement with AmpliPhi's Board of Directors with his departure from the Company being effective Monday, September 15.

The Company also announced that

AmpliPhi's Chairman, Jeremy Curnock Cook, will serve as Interim CEO and Wendy Johnson, a member of AmpliPhi's Board

or Directors, will serve as Interim COO, overseeing the Company's operations until a new CEO is appointed.

"On behalf of the entire

Board of Directors at AmpliPhi, we would like to thank Phil for his hard work, dedication and contribution to the Company over

the last three years and for laying the foundation for our future success in advancing our innovative bacteriophage technology

as a new approach to dealing with the growing threat of multi-drug resistant bacterial infections," said Mr. Cook.

Mr. Cook was responsible for

identifying and managing the acquisition of the AmpliPhi phage technology into the Company and has been instrumental in refining

the therapeutic phage platform concept over the past five years as the Company's Chairman. He has a background in microbiology

and a successful track record of building biotech and technology companies as an investor and director for over the past 30 years.

Ms. Johnson, who joined AmpliPhi's

Board of Directors earlier this year, has an extensive and successful career in investment and company building, also with a background

in microbiology and highly experienced in regulatory affairs having served as Assistant Director with the Center for Devices and

Radiological Health at the U.S. Food and Drug Administration for ten years prior to her commercial and investment career.

"AmpliPhi has emerged as

a global leader in bacteriophage development with a solid technological foundation upon which to advance into human clinical studies,"

said Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon (NYSE:XON), with whom AmpliPhi entered into an Exclusive

Channel Collaboration last year. "On behalf of Intrexon, we wish Phil well in his future endeavors and we look forward to

continue working closely with the AmpliPhi management team to deliver on the potential of phage therapies against infectious diseases."

AmpliPhi remains focused

"Over recent years the

Company has secured $35 million in financing and entered into a number of transformational collaborations including Intrexon, the

U.S. Army and the University of Leicester. Additionally, we have put in place the regulatory and manufacturing processes necessary

to progress our pipeline of phage therapies. The Company is now poised for our first program to enter Phase I development in early

2015," confirmed Mr. Cook.

About AmpliPhi BioSciences

AmpliPhi BioSciences Corporation

(OTCBB:APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial

therapeutics. The Company's product development programs target infections that are often resistant to existing antibiotic treatments.

AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE:XON), the U.S. Army, The

Royal Brompton Clinic in London, UK and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies. The

Company is headquartered in Richmond, Virginia with additional manufacturing and research operations in Ljubljana, Slovenia and

For more information, visit

www.ampliphibio.com.

Bacteriophage are naturally occurring

viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in

the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are

a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate

locally to high levels, to produce strong local therapeutic effects.

Statements in this press release

about the potential use of bacteriophages to treat bacterial infections, the development of bacteriophage-based therapies and AmpliPhi's

clinical, research and development plans are forward looking statements subject to risks and uncertainties, including without limitation

the risk that such therapies may not be successfully developed, will require extensive and expensive nonclinical and clinical testing,

may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any

foreign regulatory agency. For a further description of the risks and uncertainties that could cause actual results to differ from

those expressed in these forward-looking statements, as well as risks relating to AmpliPhi's business in general, see AmpliPhi's

Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as amended, filed with the Securities and Exchange Commission

(SEC) on September 12, 2014.

For more information regarding

AmpliPhi please contact: